|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 血管内超声去肾交感神经术治疗高血压:一项多中心,国际,单盲,随机,假手术对照试验显示文摘早期研究表明,基于射频的去肾交感神经术可降低中度高血压患者的血压。研究者研究了在没有使用抗高血压药物的情况下,使用血管内超声去。肾交感神经术是否会降低高血压患者的动态血压。 | 刘青 叶鹏 Azizi M Schmieder RE Mahfoud F Weber MA Daemen J Davies J Basile J Kirtane AJ Wang Y Lobo MD Saxena M Feyz L Rader F Lurz P Sayer J Sapoval M Levy T Sanghvi K Abraham J Sharp ASP Fisher NDL Bloch MJ Reeve-Stoffer H Coleman L Mullin C Mauri L | 2018 | 中华高血压杂志2018，26，10： | 27 |
| 2 | Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics显示文摘交往受体的蛋白质 kinase-3 (RIP3 或 RIPK3 ) 是执行 “ 的细胞的机械的必要部分; programmed”或 “ regulated”坏死。这里,我们证明那规划坏死响应许多化学疗法的代理人被激活并且贡献导致化疗的房间死亡。然而,我们证明那 RIP3 表情经常在化学疗法的死亡期间由于它的 transcriptional 开始地点, MLKL 的这样 RIP3 依赖的激活和下游地规划的坏死附近的 genomic methylation 是在癌症房间的 silenced 大部分被镇压。不过,有 hypomethylating 代理人的治疗恢复 RIP3 表示,并且从而以一种 RIP3 依赖的方式把敏感提升到 chemotherapeutics。RIP3 表示在 85% 乳癌病人与正常织物相比在肿瘤被减少,建议那 RIP3 缺乏断然在肿瘤生长 / 发展期间被选择。因为 hypomethylating 代理人在病人是相当容忍得好的,我们建议病人们可以从收到 hypomethylating 代理人与常规 chemotherapeutics 在治疗以前导致 RIP3 表示有益于的那 RIP3 缺乏的癌症。 | Gi-Bang Koo Michael J Morgan Da-Gyum Lee Woo-Jung Kim Jung-Ho Yoon Ja Seung Koo Seung I1 Kim Soo Jung Kim Mi Kwon Son Soon Still Hong Jean M Mulcahy Levy Daniel A Pollyea Craig T Jordan Pearlly Yan David Frankhouser Deedra Nicolet Kati Maharry Guido Marcucci Kyeong Sook Choi Hyeseong Cho ndrew Thorbum You-Sun Kim | 2015 | Cell Research2015，25，6： | 20 |
| 3 | 一种房颤风险评分系统的建立(Framingham心脏研究):基于社区的队列研究显示文摘背景房颤导致了发病率和病死率的显著上升。本研究旨在建立一种预测个体罹患房颤绝对风险的风险评分系统,并提供研究人员评价新危险因素的流程。方法作者评估了Framingham心脏研究中于1968年6月至1987年9月间进行了8044次检测的4764例参与者(55%为女性,年龄45~95岁)。此后,参与者被随访至房颤首发,随访期最长达10年。多变量Coxi回归确认出1(1年内罹患房颤的临床危险因素。次级分析纳入了常规超声心动图检测指标(5152例4参与者,7156次检测)对房颤风险进行再分层评估,并评价超声检测指标能否提高风险预测能力。结果4764例参与者中的457例4(10%)罹患房颤。年龄、性别、体重指数、收缩压、降压治疗、PR间期、有临床意义的心脏杂音及心力衰竭与房颤相关,并被纳入了风险评分模型(除体重指数P=0.08外,其余均为P〈0.05),模型的C统计量为0.78(95%CI0.76~0.80)。10年房颤风险随年龄变化:年龄〈65岁的人群中53例(1%)风险高于15%,而〉65岁的人群中为783例(27%)。为提高预测能力而纳入超声检测指标仅使模型C统计量略微增高,由0.78(95%C10.75~0.80)增至0.79(95%CI0.77~0.82:P=0.005)。超声心动图检测指标并不能改善风险再分层评估(P=0.18)。结论基于社区医疗中易得的临床因素建立的风险评分系统,有助于确认社区个体罹患房颤的风险,评估技术或标志物能否改善风险预测,以及针对高危个体采取预防措施。 | Renate B Schnabel Lisa M Sullivan Daniel Levy Michael J Pencina Joseph M Massaro Ralph B D'Agostino Sr Christopher Newton-Cheh Jennifer F Yamamoto Jared W Magnani Thomas M Tadros William B Kannel Thomas J Wang Patrick T Ellinor Philip A Wolf Ramachanclran S Vasan Emelia J Benjamin 黄刚(译) | 2009 | 世界临床医学2009，，9： | 2 |
| 4 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 5 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 6 | Percutaneous transluminal angioplasty balloons for endoscopic ultrasound-guided pancreatic duct interventions显示文摘BACKGROUND Endoscopic ultrasound(EUS)-guided main pancreatic duct(PD)access may be used when conventional endoscopic retrograde cholangiopancreatography(ERCP)techniques fail.The use of a percutaneous transluminal angioplasty balloon(PTAB),originally developed for vascular interventions,can be used to facilitate transmural(e.g.,transgastric)PD access and to dilate high-grade pancreatic strictures.AIM To describe the technique,efficacy,and safety of PTABs for EUS-guided PD interventions.METHODS Patients who underwent EUS with use of a PTAB from March 2011 to August 2021 were retrospectively identified from a tertiary care medical center supply database.PTABs included 3-4 French angioplasty catheters with 3-4 mm balloons designed to use over a 0.018-inch guidewire.The primary outcome was technical success.Secondary outcomes included incidence of adverse events(AEs)and need for early reintervention.RESULTS A total of 23 patients were identified(48%female,mean age 55.8 years).Chronic pancreatitis was the underlying etiology in 13(56.5%)patients,surgically altered anatomy(SAA)with stricture in 7(30.4%),and SAA with post-operative leak in 3(13.0%).Technical success was achieved in 20(87%)cases.Overall AE rate was 26%(n=6).All AEs were mild and included 1 pancreatic duct leak,2 cases of post-procedure pancreatitis,and 3 admissions for post-procedural pain.No patients required early re-intervention.CONCLUSION EUS-guided use of PTABs for PD access and/or stricture management is feasible with an acceptable safety profile and can be considered in patients when conventional ERCP cannulation fails. | Jad P AbiMansour Barham K Abu Dayyeh Michael J Levy Andrew C Storm John A Martin Bret T Petersen Ryan J Law Mark D Topazian Vinay Chandrasekhara | 2022 | World Journal of Gastrointestinal Endoscopy2022，14，8： | 2 |
| 7 | End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients显示文摘AIM To determine if end-stage renal disease (ESRD) is a risk factor for post endoscopic retrograde cholangio-pancreatography (ERCP) adverse events (AEs). METHODS We performed a retrospective cohort study using the Nationwide Inpatient Sample (NIS) 2011-2013. We identified adult patients who underwent ERCP using the International Classification of Diseases 9^(th) Revision (ICD-9-CM). Included patients were divided into three groups: ESRD, chronic kidney disease (CKD), and control. The primary outcome was post-ERCP AEs including pancreatitis, bleeding, and perforation determined based on specific ICD-9-CM codes. Secondary outcomes were length of hospital stay, in-hospital mortality, and admission cost. AEs and mortality were compared using multivariate logistic regression analysis.RESULTS There were 492175 discharges that underwent ERCP during the 3 years. The ESRD and CKD groups contained 7347 and 39403 hospitalizations respectively, whereas the control group had 445424 hospitalizations. Post-ERCP pancreatitis (PEP) was significantly higher in the ESRD group (8.3%) compared to the control group (4.6%) with adjusted odd ratio (aOR) = 1.7 (95% CI: 1.4-2.1, ~aP < 0.001). ESRD was associated with significantly higher ERCP-related bleeding (5.1%) compared to the control group 1.5% (aOR = 1.86, 95%CI: 1.4-2.4, ~aP < 0.001). ESRD had increased hospital mortality 7.1% vs 1.15% in the control OR = 6.6 (95%CI: 5.3-8.2, ~aP < 0.001), longer hospital stay with adjusted mean difference (aMD) = 5.9 d (95% CI: 5.0-6.7 d, ~aP < 0.001) and higher hospitalization charges aMD = $+82064 (95%CI: $68221-$95906, ~aP < 0.001). CONCLUSION ESRD is a risk factor for post-ERCP AEs and is associated with higher hospital mortality. Careful selection and close monitoring is warranted to improve outcomes. | Tarek Sawas Fateh Bazerbachi Samir Haffar Won K Cho Michael J Levy John A Martin Bret T Petersen Mark D Topazian Vinay Chandrasekhara Barham K Abu Dayyeh | 2018 | World Journal of Gastroenterology2018，24，41： | 2 |
| 8 | 抗体/腺病毒复合物为载体的基因定位递送显示文摘临床基因治疗方案中基因载体在疾病部位的靶向递送仍是急待解决的问题。本研究将腺病毒与一种生物素化的特异性抗腺病毒六邻体的多克隆IgG结合,固定于结合了亲和素的胶原蛋白膜上,成功获得腺病毒载体基因靶向定位递送体系。体外稳定性研究结果表明该体系中病毒载体可有效保持活性。通过这种特异性抗体偶联方式,将携带单纯疱疹胸苷激酶(HSVtk)编码基因片断的腺病毒结合在胶原膜上转染大鼠平滑肌细胞(A10),加入更昔洛韦(ganciclovir)后,只有生长在胶原膜上及膜邻近50μm内的细胞被杀死。在使用非特异性抗体的对照实验中,整个培养基范围内的细胞几乎全被杀死。以绿色荧光蛋白(GFP)为报告基因对猪的心肌进行转基因实验,结果显示注射特异性抗体偶联病毒的胶原凝胶比直接注射病毒悬液获得更高效的心室基因表达。所有研究结果表明,通过生物素和特异性抗体使病毒载体固定在胶原蛋白基质上,可达到有效的局部定位基因表达,避免向非病灶部位的扩散,是基因治疗中一种极具发展潜力的载体定位递送方法。 | 宋存先 王满燕 RJ Levy S Tallapragada S DeFelice J T Hinson | 2005 | 中国生物医学工程学报2005，24，5： | 2 |
| 9 | Concepts of blood transfusion in adults显示文摘 | Lawrence T Goodnough Jerrold H Levy Michael F Murphy | 2013 | The Lancet2013，，9880： | 2 |
| 10 | Bidirectional relation between inflammation and coagulation 显示文摘 | Levi M van der Poll T Bailer HR | 2004 | Circulation2004，109，22： | 1 |
| 11 | The role of public policies in reducing smoking prevalence in California: Results from the California Tobacco Policy Simulation Model显示文摘 | David T Levy Andrew Hyland | 2007 | Health Policy2007，82，2： | 1 |
| 12 | Probing of the spliceoseme with site-specifically derivatized 5' splice site RNA oligonucleotides显示文摘 | LEVY T KOIS P | 1998 | RNA1998，4，： | 1 |
| 13 | Routine use of auxiliary partial orthotopic liver transplantation for children with fulminant hepatic failure:Preliminary report显示文摘 | Kato T Selvaggi G Levi D | 2006 | Transplant Proc2006，38，10： | 1 |
| 14 | Schottky-barrier inhomogeneity at epitaxial NiSi2 interfaces on Si(100) 显示文摘 | TUNG R T LEVI A F J SULLIVAN J P | 1991 | Phys Rev Lett1991，66，1： | 1 |
| 15 | Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore显示文摘 | Schneiders T Amyes SG Levy SB | 2003 | Antimicrob Agents Chemother2003，47，9： | 1 |
| 16 | Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation 显示文摘 | Levi M de Jonge E van der Poll T | 2001 | Crit Care Med2001，29，7： | 1 |
| 17 | Qrigin of excess capacitance at intimate schottky contacts显示文摘 | Levi A F J Tung R T Anzlowar M | 1987 | Phys RevLett1987，60，1： | 1 |
| 18 | Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases 显示文摘 | Bossard M J Tomaszek T A Levy M A | 1999 | Biochemistry1999，38，15： | 1 |
| 19 | A Phase I study of TNP-470 administered to patients with advanced squamouse cell cancer of the cervix显示文摘 | Kudelka AP Levy T Verschraegen CF | 1997 | Clin Cancer Res1997，3，： | 1 |
| 20 | Anticoagulant therapy for acute lung injury or pneumonia显示文摘 | Sehultz M J Levi M Van der Poll T | 2003 | Curr Drug Targets2003，4，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员